Adamas Pharmaceuticals Inc short interest in 2021
In 2021, Adamas Pharmaceuticals Inc's disclosed short interest ran from 4.22% of shares outstanding on 15 Jan 2021 to 1.04% on 15 Nov 2021, a change of -3.18 percentage points. The year's high was 8.39% on 15 Apr 2021 and its low 1.04% on 15 Nov 2021, averaging 5.16% across 21 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 18.83 days on 15 Sep 2021. Full history: Adamas Pharmaceuticals Inc.
Cite this page
By year: 2018 · 2019 · 2020 · 2021
2021 in figures
- Start of year
- 4.22% (15 Jan 2021)
- End of year
- 1.04% (15 Nov 2021)
- Change
- -3.18 pp
- High
- 8.39% (15 Apr 2021)
- Low
- 1.04% (15 Nov 2021)
- Average
- 5.16%
- Highest days to cover
- 18.83 (15 Sep 2021)
- SEC filings marked
- 8
Every report in 2021
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2021 | 4.22% | 8.26 | results (8-K) |
| 29 Jan 2021 | 6.22% | 3.27 | |
| 12 Feb 2021 | 3.24% | 1.00 | |
| 26 Feb 2021 | 6.97% | 1.98 | 10-K filed, results (8-K) |
| 15 Mar 2021 | 7.88% | 4.37 | |
| 31 Mar 2021 | 8.25% | 6.27 | |
| 15 Apr 2021 | 8.39% | 11.79 | |
| 30 Apr 2021 | 5.33% | 5.37 | |
| 14 May 2021 | 5.04% | 7.91 | 10-Q filed, results (8-K) |
| 28 May 2021 | 4.87% | 10.41 | |
| 15 Jun 2021 | 4.67% | 5.08 | |
| 30 Jun 2021 | 4.72% | 8.09 | |
| 15 Jul 2021 | 5.05% | 8.29 | |
| 30 Jul 2021 | 5.42% | 13.88 | |
| 13 Aug 2021 | 5.53% | 6.58 | 10-Q filed, results (8-K) |
| 31 Aug 2021 | 5.38% | 10.49 | |
| 15 Sep 2021 | 5.51% | 18.83 | |
| 30 Sep 2021 | 5.19% | 13.75 | |
| 15 Oct 2021 | 3.51% | 1.00 | |
| 29 Oct 2021 | 1.93% | 1.00 | |
| 15 Nov 2021 | 1.04% | 1.00 | 10-Q filed |
See also: Adamas Pharmaceuticals Inc's full history · most shorted US stocks of 2021 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.